Top Markets
#1 Black Phoenix Black Phoenix +21,336.93%
#2 Nesa Nesa +789.76%
#3 Cortex Cortex +67.88%
#4 Kinesis Silver Kinesis Silver +55.45%
#5 QuantixAI QuantixAI +23.76%
#6 EXOD EXOD +22.78%
#7 Cash Cat Cash Cat +18.71%
#8 Alchemist AI Alchemist AI +14.59%
#9 Pons Pons +14.37%
#10 PondCoin PondCoin +13.60%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Shanghai Junshi Biosciences Co., Ltd. Shanghai Junshi Biosciences Co., Ltd.

Shanghai Junshi Biosciences Co., Ltd.

688180
Classifica tra le azioni #3505
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise... Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise dedicated to the research, development, and marketing of innovative therapeutic agents. Operating within the People's Republic of China, their focus spans critical medical areas such as oncology, metabolic diseases, autoimmune disorders, neurological conditions, and infectious diseases. Among its principal offerings is JS001, commercialized as TUOYI. This recombinant humanized anti-PD-1 monoclonal antibody has received approval for a broad spectrum of cancer indications, including various forms of melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. Beyond TUOYI, Junshi Biosciences boasts a robust pipeline of investigational drugs. These include UBP1211, a biosimilar of Humira, targeting conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody aimed at hyperlipidemia; and UBP1213, a recombinant humanized anti-BLyS monoclonal antibody in injectable form. Further developments encompass JS501, a biosimilar to Avastin; JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, identified as a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. The company has also established strategic collaborations. Notably, it partners with Eli Lilly and Company on the co-development of therapeutic antibodies intended for the prevention and treatment of COVID-19, the illness caused by the SARS-CoV-2 novel coronavirus. Additionally, an alliance with Coherus Biosciences, Inc. facilitates the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. maintains its corporate headquarters in Shanghai, People's Republic of China.
Prezzo delle azioni
$5.14
Capitalizzazione di mercato
$5.24B
Variazione (1 giorno)
0.65%
Variazione (1 anno)
-18.58%
Paese
CN
Scambia Shanghai Junshi Biosciences Co., Ltd. (688180)

Categoria

Healthcare
Storico del prezzo dell'azione per Shanghai Junshi Biosciences Co., Ltd. (688180)
Prezzo di chiusura più alto: $5.53 il 2026-08-01

Prezzo di chiusura più basso: $17.35 il 2020-07-01
Storico del prezzo dell'azione di Shanghai Junshi Biosciences Co., Ltd. dal 2020 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) 5.79%
2025 22.85%
2024 -31.93%
2023 -28.79%
2022 -9.13%
2021 -14.02%
2020 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $553.09 42.85%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.02K 44.02%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $158.64 541.49%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.62 -12.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $769.15 6.90%
CH